Congress caps inhaler costs at $15 for asthma, COPD patients nationwide

What it does

This bill caps patient cost-sharing for prescription inhalers and nebulizers used to treat asthma and COPD at $15 per 30-day supply across private insurance, Medicare Part B, Medicare Part D, and creates a federal payment program for uninsured individuals. The bill applies to all maintenance, reliever, rescue, and equipment-related inhaler products with medically accepted indications, and ensures these costs count toward deductibles and out-of-pocket maximums.

Why we flagged it

The bill's operative mechanism is a price ceiling ($15 per 30-day supply) and deductible waiver for a specific class of essential medications. This is direct cost regulation, not a subsidy or tax provision.

What the text implies

• The $15 cap applies uniformly across all inhalers regardless of acquisition cost or therapeutic class, potentially creating supply-chain pressure on lower-cost generics and incentivizing manufacturers to bundle or reformulate products to avoid the cap.
• Medicare Part D cost-sharing caps may shift financial burden from beneficiaries to plan sponsors and the federal government, potentially affecting premium structures for all Part D enrollees in subsequent years.
• The uninsured payment program (Section 399V–8) creates a new federal claims-submission infrastructure and open-ended appropriations requirement, with no explicit funding authorization or spending cap.
• HDHP and catastrophic plan safe harbors (Section 223 and 1302 amendments) allow these plans to waive deductibles for inhalers without losing tax-advantaged status, potentially fragmenting cost-sharing rules across plan types.
• The bill does not address manufacturer rebates, formulary restrictions, or prior authorization requirements, which may persist as non-price barriers to access despite the $15 cap.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens with asthma or COPD gain direct, measurable relief: lower out-of-pocket costs for essential maintenance medications, removal of deductible barriers, and coverage extension to uninsured individuals. The $15 cap is a concrete price floor that reduces financial barriers to life-sustaining respiratory care.

Who stands to gain

• patients with asthma and COPD (primary beneficiaries)
• uninsured individuals with respiratory disease
• Medicare beneficiaries
• group health plan participants

Named in the bill

BMY (Bristol Myers Squibb), GH (Greentree Pharmaceuticals / Grifols), PFE (Pfizer), DVA (DaVita HealthCare Partners), JNJ (Johnson & Johnson), HHS (Department of Health and Human Services), CMS (Centers for Medicare & Medicaid Services), Medicare Part B, Medicare Part D, ERISA group health plans, ACA individual and group markets

Where it stands

13 cosponsors: 13 Democrats.

• Sep 10, 2025 — Introduced · Congress.gov: “Introduced in House”
• Sep 10, 2025 — Referred to House Committee on Education and Workforce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $190,000 in lobbying spend. A filing names 50 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Kweisi Mfume, the sponsor, reported $253,300 in PAC receipts in the 2026 cycle.

• American Lung Association — $190,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.